RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025

Feb 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-14

Reporting Person: Smith Hunter C (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-16	Common Stock	M	6600	—	Acquired	112144	Direct
2025-02-19	Common Stock	S	2215	$57.22	Disposed	109929	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-14	Restricted Stock Units	$	A	41650	Acquired		Common Stock (41650)	Direct
2025-02-14	Stock Options (Right to Buy)	$56.69	A	62500	Acquired	2035-02-13	Common Stock (62500)	Direct
2025-02-16	Restricted Stock Units	$	M	6600	Disposed		Common Stock (6600)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.

F3: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.

F4: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

F5: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.